Notice of Intent to Publish a Request for Applications for the Blueprint for Neuroscience Grand Challenge: New Drugs for Diseases and Disorders of the Nervous System (U01)

Notice Number: NOT-NS-10-002

Key Dates
Release Date:  October 16, 2009

Issued by
NIH Blueprint for Neuroscience Research ( and its member institutes, offices, and centers:

National Center for Complementary and Alternative Medicine (NCCAM) (
National Center for Research Resources (NCRR) (
National Eye Institute (NEI) (
National Institute on Aging (NIA) (
National Institute on Alcohol Abuse and Alcoholism (NIAAA) (
National Institute of Biomedical Imaging and Bioengineering (NIBIB) (
National Institute of Child Health and Human Development (NICHD) (
National Institute on Drug Abuse (NIDA) (
National Institute on Deafness and Other Communication Disorders (NIDCD) (
National Institute of Dental and Craniofacial Research (NIDCR) (
National Institute of Environmental Health Sciences (NIEHS) (
National Institute of General Medical Sciences (NIGMS) (
National Institute of Mental Health (NIMH) (
National Institute of Neurological Disorders and Stroke (NINDS) (
National Institute of Nursing Research (NINR) (
Office of Behavioral and Social Sciences Research (OBSSR) (


The NIH Blueprint for Neuroscience Research (
intends to issue a Request for Applications (RFA) to solicit projects for the Blueprint Grand Challenge for New Drugs for Diseases and Disorders of the Nervous System. The goal is to support the development of new small molecule drugs that will transform the treatment of neurological, psychiatric, or other nervous system diseases or conditions. These awards will provide 1) funding to support biological testing of compounds during development and 2) access to technical, infrastructure, and advisory resources to enable investigators to translate promising lead small molecule compounds into drugs that have completed phase 1 clinical trials. Applicants to this RFA must have:

Resources to conduct drug development activities other than bioactivity testing will be provided to the successful applicants by the NIH Blueprint. These include medicinal chemistry optimization, pharmacology and toxicology testing and Phase 1 clinical testing. Successful applicants will retain ownership of the intellectual property for compounds they develop through this program.

This notice is being provided to allow potential applicants sufficient time to develop responsive projects and necessary collaborations. The RFA is expected to be published in the NIH Guide for Grants and Contracts in April 2010 with an anticipated receipt date in August 2010.

This RFA will use the U01 cooperative agreement mechanism.



Interested parties may contact:

Jill Heemskerk Ph.D.
National Institute of Neurological Disorders and Stroke
National Institutes of Health
6001 Executive Boulevard, Room 2229
Bethesda, MD 20892-9525
EXPRESS/COURIER:  Rockville, MD 20852

Weekly TOC for this Announcement
NIH Funding Opportunities and Notices

Office of Extramural Research (OER) - Home Page Office of Extramural
Research (OER)
  National Institutes of Health (NIH) - Home Page National Institutes of Health (NIH)
9000 Rockville Pike
Bethesda, Maryland 20892
  Department of Health and Human Services (HHS) - Home Page Department of Health
and Human Services (HHS) - Government Made Easy

Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.